Metformin During Breast Cancer: Dosing and Supplement Safety
Metformin is being studied in breast cancer clinical trials across hormone receptor-positive, HER2-positive, and triple negative subtypes. This guide reviews trial dosing, key supplement interactions including berberine and curcumin, and the safety monitoring patients need when metformin is part of their care plan.
Fenbendazole for Ovarian Cancer: Evidence and Safety
Fenbendazole is a veterinary antiparasitic drug attracting growing interest among ovarian cancer patients. This article reviews the 2024 preclinical findings, documented liver injury risks, and interaction concerns with standard chemotherapy that every patient should discuss with their oncologist.
CML on Dasatinib: Managing Fluid and Bone Side Effects
Fluid retention and bone aches affect a significant proportion of patients taking dasatinib for chronic myeloid leukemia. This guide covers how care teams manage each side effect and what daily steps may help sustain quality of life during long-term targeted therapy.
Chronic Myeloid Leukemia on Imatinib: Managing Targeted Therapy Side Effects and Quality of Life in Long-Term Treatment
Most people with chronic-phase CML take imatinib for years or even decades. This article covers what the evidence says about managing the most common long-term side effects - nausea, edema, fatigue, and muscle cramps - and why consistent adherence matters as much as the drug itself.
Low-Dose Naltrexone for Cancer Pain: Dosing, Evidence, and Safety with Chemotherapy and Hormonal Therapies
Low-dose naltrexone (LDN) is being studied off-label for refractory cancer-related pain. This article reviews typical dosing, early clinical evidence, and key safety considerations for people on chemotherapy or hormonal therapy.
